Comparative Pharmacology
Head-to-head clinical analysis: ALA SCALP versus HYFTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALA SCALP versus HYFTOR.
ALA-SCALP vs HYFTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (PpIX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), PpIX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
HYFTOR (solithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide bond formation and inhibiting translation. It also exhibits anti-inflammatory effects by modulating cytokine production and neutrophil activity.
Topical application of a 5% solution to the scalp twice daily.
0.5% gel, apply a thin layer to the treatment area once daily at bedtime. Duration: 4-8 weeks.
None Documented
None Documented
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life is approximately 5.5 hours (range: 3.2–9.1 h), supporting twice-daily dosing.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily hepatic metabolism; minimal renal excretion (<1% as unchanged drug). Eliminated via feces (84%) and urine (4%) as metabolites.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid